Keybank National Association OH Purchases New Holdings in Guardant Health, Inc. $GH

Keybank National Association OH acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 6,261 shares of the company’s stock, valued at approximately $391,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GH. AQR Capital Management LLC increased its stake in shares of Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after buying an additional 25,831 shares during the last quarter. Empowered Funds LLC acquired a new position in Guardant Health during the 1st quarter worth $274,000. Janney Montgomery Scott LLC increased its position in shares of Guardant Health by 277.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 20,574 shares of the company’s stock worth $1,071,000 after purchasing an additional 15,128 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Guardant Health by 15.9% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,786 shares of the company’s stock worth $249,000 after purchasing an additional 656 shares during the last quarter. Finally, IFP Advisors Inc raised its stake in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GH. Stifel Nicolaus lifted their price target on Guardant Health from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Guggenheim upped their price target on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, January 26th. BTIG Research raised their price objective on Guardant Health from $100.00 to $140.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Mizuho set a $135.00 target price on shares of Guardant Health in a research note on Friday, January 9th. Finally, Leerink Partners raised their price target on shares of Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Twenty-one investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.86.

Guardant Health Stock Performance

Guardant Health stock opened at $101.85 on Friday. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74. The company has a 50-day simple moving average of $106.38 and a 200-day simple moving average of $81.68. The firm has a market capitalization of $12.84 billion, a P/E ratio of -31.73 and a beta of 1.63.

Insider Transactions at Guardant Health

In related news, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total value of $9,402,458.30. Following the sale, the chief executive officer directly owned 2,047,143 shares in the company, valued at $212,534,386.26. This trade represents a 4.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at approximately $17,671,826.15. The trade was a 37.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 434,627 shares of company stock worth $45,592,052 in the last quarter. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.